BOTHELL, Wash., April 06, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) , a clinical-stage biopharmaceutical company, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering. In connection with this offering, Alder expects to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of common stock.
J.P. Morgan Securities LLC, Leerink Partners LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering.
A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC), and was effective on filing on June 2, 2015. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at 1-866-803-9204, or by email at [email protected]; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by phone at 1-800-808-7525 ext. 6142, or by email at [email protected]; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by phone at 1-800-326-5897, or by email at [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
| Media Contacts: David Schull or Lena Evans Russo Partners (212) 845-4271 (212) 845-4262 [email protected] [email protected] | Investor Relations Contacts: David Walsey Alder BioPharmaceuticals, Inc. (425) 408-8032 [email protected] |


DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 



